The class action lawsuit against Zoetis Inc. did not emerge from nowhere. It grew out of a specific chain of events that began months before the first legal filing, when regulators started raising questions about one of the company’s key animal drugs. On January 14, 2025, the Class Period opened.
By then, Zoetis had been selling Librela, a monoclonal antibody treatment for osteoarthritis pain in dogs, for years. The drug was a significant revenue driver.
But that changed when the U.S. Food and Drug Administration issued safety warnings about neurological complications tied to the medication. Veterinarians began writing fewer prescriptions. The drop was not subtle.
The complaint, filed by the Schall Law Firm in Los Angeles, alleges that Zoetis executives knew about the weakening prescription growth but continued to make false and misleading statements to the market. The alleged deception ran until May 6, 2026 — a stretch of roughly 16 months.
Librela was not the only problem. The lawsuit also points to Zoetis’ Trio product, a combination vaccine, which the company was losing market share on. And then there were the dermatology drugs Apoquel and Cytopoint — both heavy hitters for the company — also reportedly losing ground.
Three product lines under pressure at once. That is the kind of situation that can crater a stock if investors know the real numbers. The core allegation is straightforward: Zoetis’ public statements during the Class Period were materially misleading.
The company said one thing. The facts, according to the lawsuit, said another.
Investors who bought ZTS shares based on those statements may have paid too much for a stock that did not reflect the company’s actual condition. Brian Schall, the firm’s founder, is now fielding calls from shareholders. His number is 310-301-3335.
The deadline to contact the firm is July 27, 2026. That is roughly five weeks from the date this lawsuit was announced.
Zoetis trades on the New York Stock Exchange under the ticker ZTS. It is one of the larger animal health companies in the world. That scale makes the allegations particularly consequential.
If the claims hold, the case could serve as a reminder that even established pharmaceutical firms face real consequences when product lines stumble and the public statements do not match the private data. The lawsuit invokes the Securities Exchange Act of 1934 — the same law that governs disclosure requirements for publicly traded companies. The act exists to protect investors from exactly this kind of alleged behavior: companies saying everything is fine when it is not.
For now, the case is in its early stages. The Schall Law Firm is seeking to lead the class action.
That means gathering investors who bought Zoetis securities during the Class Period and building a unified claim. The firm’s website, www.schallfirm.com, has details on how to join. What matters most to the average shareholder is timing.
The July 27 deadline is firm. After that, investors who bought during the Class Period may lose their chance to participate in any potential recovery.
The firm is clear about that. The FDA safety warnings on Librela were the spark. The alleged misleading statements were the fuel.
Now a federal court will have to sort out what Zoetis knew, when it knew it, and whether the company broke the law by saying otherwise.
{“@context”: “https://schema.org”, “@type”: “NewsArticle”, “headline”: “FDA Questions Led to Zoetis Securities Fraud Class Action Lawsuit”, “description”: “The class action lawsuit against Zoetis Inc. did not emerge from nowhere. It grew out of a specific chain of events that began months before…”, “datePublished”: “2026-06-22T13:10:00+00:00T09:30:00+00:00”, “author”: {“@type”: “Person”, “name”: “Ava Anderson”}, “publisher”: {“@type”: “Organization”, “name”: “InfoPulse Today”, “url”: “https://newsfeed.infopulsetoday.com/”}}
